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Regulation of cell cycle progression
occurs at several checkpoints, and
genetic alterations that affect the expres-
sion or function of various regulator pro-
teins have been implicated in virtually
every type of cancer cell, which charac-
teristically exhibit growth rates higher
than those of their normal cellular coun-
terparts.The G1/S checkpoint is of partic-
ularly broad importance in cancer, as it
determines whether or not a cell will
commit to a round of cell division.
Regulation of the G1/S checkpoint by
D cyclins, cyclin-dependent kinases
(CDKs), CDK inhibitors (CKIs), and the
retinoblastoma tumor suppressor protein
pRB has been discussed in detail recent-
ly in the pages of Cancer Cell (Evans et
al., 2003) and will be reviewed here only
briefly. pRB plays a pivotal role by
sequestering the transcription factor
E2F, whose transcriptional targets
include genes needed for S phase entry.
Active CDKs 4 and 6 relieve this block by
phosphorylating pRB, which disrupts its
association with E2F. CDK4/6 activity is
dependent upon interaction with D
cyclins, which are normally regulated
during the cell cycle at multiple levels,
including transcription, protein stability,
posttranslational modifications, and sub-
cellular localization. D cyclins also pro-
mote S phase entry by sequestering
p21CIP1 and p27KIP1, which are negative
regulators of CDK2.
Mammals have three D cyclins
(cyclins D1–D3), polypeptides of ?34
kDa that are thought to be functionally
interchangeable within a given cell
(Ciemerych et al., 2002); however, not
all cells express multiple D cyclins. In
this issue of Cancer Cell, Sicinski and
coworkers (Sicinska et al., 2003) report
that cyclin D3−/− mice suffer from an iso-
lated defect in thymocyte development
characterized by a marked deficit in
CD4+CD8+ “double-positive” (DP) T
cells. This phenotype stems from a
nonredundant role for cyclin D3 in the
maturation of CD4−CD8− “double-nega-
tive” (DN) T cells, the precursors of DP T
cells. In the mouse, developing DN T
cells successively pass through four
stages (DN-1–DN-4) defined by differ-
ential expression of CD44 and CD25
(Figure 1). Cyclin D3−/− thymocytes fail
to undergo the proliferative burst that
normally accompanies the DN-3 to DN-
4 transition. Pro-proliferative signals
depend on the pre-T cell receptor com-
plex (pre-TCR), which contains TCRβ, a
“surrogate” α chain called pre-Tα,
CD3ε, γ, and ζ, and the tyrosine kinase
p56LCK. As would be predicted from the
cyclin D3−/− phenotype, normal DN-3 to
DN-4 transition coincides with a dramat-
ic upregulation of cyclin D3, and this
upregulation fails to occur in p56LCK−/−
mice, placing cyclin D3 downstream of
pre-TCR signals.
These findings add cyclin D3 to a
cohort of proteins that appear to partici-
pate in a coordinated set of signaling
events required for the DN proliferative
burst (Figure 1). An initiating event
appears to be engagement of Notch1 by
yet-to-be clearly defined ligand(s), which
produces signals that upregulate pre-Tα
(Reizis and Leder, 2002), setting the
stage for assembly of the pre-TCR sig-
naling complex. Pre-Tα signals mediate
multiple events during β-selection, which
include in addition to proliferation, TCRβ
allelic exclusion, induction of differentia-
tion, and rescue from apoptosis. Sicinska
et al. suggest signals produced by the
pre-TCR complex upregulate cyclin D3,
which provides the essential proliferative
drive needed for expansion of the DN-4
pool, the immediate precursors of DP
thymocytes. While this picture has been
mostly delineated from work in the
mouse, it is believed that similar signals
and mechanisms apply to human T cell
development.
Given the role for cyclin D3 in normal
thymocyte proliferation, Sicinska et al.
asked if cyclin D3 might be specifically
required for the growth of at least some
forms of precursor-T cell acute lym-
phoblastic leukemia/lymphoma (T-ALL)
tumors derived from immature T cells.
The authors first pursued this by study-
ing the effect of cyclin D3 deficiency on
murine T-ALL models initiated variously
by transgenes encoding constitutively
active p56LCK, retroviruses expressing
activated forms of Notch1, or p53 defi-
ciency. All of these models produce
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Figure 1. Expression patterns of proteins required for the proliferative burst during CD4−CD8−
double-negative pre-T cell maturation
Activation of Notch1 signaling in early thymic T cell progenitors initiates a coordinated series of
events that lead to the assembly of the pre-TCR signaling complex and upregulation of cyclin
D3. The resultant proliferative burst is eventually terminated by expression of αβ TCR complexes.
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mainly CD4+/CD8+ T-ALLs, but only
those tumors caused by Notch1 and
p56LCK signals require pre-TCR function
for their development. Consistent with
the pathway outlined in Figure 1, cyclin
D3 deficiency prevented Notch1
leukemias and delayed the onset of
tumors caused by p56LCK. In contrast, the
development of T-ALL in the p53−/− back-
ground was unaffected by cyclin D3 defi-
ciency. The authors’ analysis was then
extended to primary human T-ALLs by
nearest neighbor analysis, which
revealed a strong positive correlation
between cyclin D3 and p56LCK mRNA
expression. Finally, the authors showed
that RNAi-mediated knockdown of cyclin
D3 causes a G0/G1 growth arrest in a
number of established human T-ALL cell
lines, including one (SUP-T1) known to
require Notch1 signals for growth and
survival.
These studies support cyclin D3 as a
rational target in certain forms of T-ALL,
adding it to a list of neoplasms in which
specific D cyclins are sometimes solely
responsible for the G1 cell cycle drive,
such as cyclin D1 in breast carcinoma
(Yu et al., 2001). Other tumor types (e.g.,
mantle cell lymphoma), which almost
always have dysregulation of particular
D cyclins, could also prove sensitive to
specific inhibitors. Because most cells
express multiple D cyclins, inhibitors of
individual D cyclins could, in principle,
disrupt the growth of tumors expressing
single D cyclins while causing less toxic-
ity than general cell cycle inhibitors. But
can such inhibitors be developed? Short
of a dramatic breakthrough in RNAi
delivery, this approach needs to rely on
small molecule inhibitors of specific
cyclin D-CDK4/6 interactions. While D
cyclins show some sequence divergence
(50%–60% of amino acid residues are
identical across the family), it is likely the
key contacts with CDK4/6 are highly con-
served, which might make this approach
untenable. A high-resolution structure for
cyclin D-CDK4/6 complexes (currently
unknown) is needed to clarify this issue.
A strategy more likely to be fruitful is
targeting of pathway(s) that promote D
cyclin activity in T-ALL, which character-
istically have a high growth fraction. In
this regard, it is worth asking whether the
same signals that drive proliferation dur-
ing the DN to DP transition contribute to
the growth of human T-ALL cells. Human
T-ALLs are genetically and phenotypical-
ly heterogeneous, but a sizable fraction
(?60%) express pre-Tα and TCRβ
(Asnafi et al., 2003). Multiple pre-TCR
components (pre-Tα [Bellavia et al.,
2002], TCRβ, and the adaptor molecule
SLP76 [Allman et al., 2001]) are essen-
tial for Notch-mediated leukemogenesis
in the mouse, and some T-ALLs require
continued Notch signaling for growth
(Weng et al., 2003); together with the
cyclin D3 knockdown data of Sicinska et
al., these findings suggest the signals
required for the normal proliferative burst
may interact in analogous ways to pro-
mote tumor growth. However, many
issues have yet to be explored. It will be
of interest to see if enforced expression
of cyclin D3 is sufficient to cause murine
T-ALL, even in Notch/pre-TCR-deficient
backgrounds. Of broader significance,
the signals that operate upstream of D
cyclins in established T-ALLs are
unknown; Notch- and pre-TCR-mediated
signals appear to be excellent candi-
dates for such a role, but direct evidence
is lacking at this point. Further, human T-
ALLs often harbor deletions, mutations,
and/or epigenetic aberrations that result
in defective CKI expression (Batova et
al., 1997), indicating that problems with
braking mechanisms controlling G1/S
progression may be as important as pro-
proliferative signals. More detailed
knowledge of the events that promote
cyclin D activity in various T-ALL sub-
types will be needed if rational antiprolif-
erative therapies are to be developed
successfully.
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